European Pharmaceutical Market Access, Pricing and Reimbursement

This year's agenda will have a strong focus on the future of pricing and reimbursement.

Key topics include:

-Updates on AMNOG and its implication on pricing and reimbursement
-How biosimilars are affecting your pricing strategy
-Capture on emerging markets’ regulatory framework to adapt your market access and P&R models
-Orphan drugs using recent examples to highlight the impact on pricing
-Cancer drug funding and budget cuts in the UK
-Innovative solutions beyond the pill
-Japanese, American, Nordic and Turkish regional update

Key speakers in 2016:

-Bertram Häussler, Chairman of the Board of Management, IGES
-Simone Breitkopf, Head HEOR, Governmental and Public Affairs, Alcon
-Ulf Staginnus, Head Market Access Oncology, Region Europe, Baxalta
-Gordon Spencer, Regional Market Access Lead - EU & Canada, Shire International GmbH
-Alexander Natz, Secretary General, EUCOPE
-David Watson, Director of Pricing and PPRS, Association of the British Pharmaceutical Industry
-Panos Kefalas, Head of Health Economics and Market Access, Cell & Gene Therapy Catapult
and many more...

Don't miss the workshop!

HTA and reimbursement decisions for innovative medicines
Workshop Leader: Patrick Mollon, Former Director of Health Economic & Outcomes Research, Novartis; HEOR Director, PMHE2020